ClinicalTrials.gov
ClinicalTrials.gov Menu

A Study to Evaluate the Use of Bosentan in Patients With Exercise Induced Pulmonary Arterial Hypertension Associated With Connective Tissue Disease

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00864201
Recruitment Status : Unknown
Verified March 2009 by McMaster University.
Recruitment status was:  Not yet recruiting
First Posted : March 18, 2009
Last Update Posted : March 18, 2009
Sponsor:
Collaborator:
Actelion
Information provided by:
McMaster University

Brief Summary:
The primary objectives of this exploratory study are to evaluate the effects of bosentan on hemodynamics (via cardiac catheterization) during exercise in patients with Pulmonary Arterial Hypertension (PAH) who have abnormal hemodynamics during exercise but normal hemodynamics at rest. The authors hypothesize that early treatment may change the course of disease progression by improving hemodynamics during exercise, thus delaying disease progression.

Condition or disease Intervention/treatment Phase
Hypertension, Pulmonary Connective Tissue Disease Drug: bosentan Phase 3

Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 10 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Pilot Study to Evaluate the Effect of Bosentan in Patients With Exercise Induced Pulmonary Arterial Hypertension Associated With Connective Tissue Disease
Study Start Date : April 2009
Estimated Primary Completion Date : April 2010
Estimated Study Completion Date : April 2010


Arm Intervention/treatment
Experimental: bosentan Drug: bosentan
bosentan 62mg bid x 4 weeks, followed by bosentan 125mg bid x 20 weeks




Primary Outcome Measures :
  1. The primary outcome is the change in the following hemodynamics during exercise: pulmonary vascular resistance (PVR), mean pulmonary arterial pressure (mPAP), cardiac output∕cardiac input (CO∕CI), mean right arterial pressure (mRAP) [ Time Frame: 6 months ]

Secondary Outcome Measures :
  1. Change in hemodynamics at rest: pulmonary vascular resistance (PVR), mean pulmonary arterial pressure (mPAP), cardiac output/cardiac input (CO∕CI), mean right arterial pressure (mRAP) [ Time Frame: 6 months ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Men or women ≥ 18 years of age
  • For female patients, only non-pregnant women who are surgically sterile, postmenopausal or have documented infertility (over 50 years of age and amenorrheic for at least 1 year), or those of childbearing potential using one of the following methods of contraception:

    • Barrier-type devices (e.g., condom, diaphragm) used ONLY in combination with a spermicide. A double-barrier method is recommended.
    • Intrauterine devices (IUDs)
    • Oral contraceptives, if used in combination with a barrier method
  • Body weight of 40 kg or higher
  • Patients diagnosed with connective tissue disease
  • Hemodynamics at rest, based on cardiac catheterization, should be as follows:

    • Mean pulmonary arterial pressure (mPAP) : 18 - 25 mmHg
    • PCWP ≤ 15 mmHg
  • Hemodynamics during exercise, based on cardiac catheterization, should be as follows: mPAP > 30 mmHg
  • Provide written informed consent

Exclusion Criteria:

  • PAH associated with any other condition
  • Severe obstructive lung disease : FEV1∕ FVC <0.5
  • Total lung capacity <60% of normal predicted value
  • Unable or unwilling have a cardiac catheterization procedure
  • Acute or chronic impairment (other than dyspnea), limiting the ability to comply with study requirements (6-MWT)
  • Psychotic, addictive or other disorder limiting the ability to provide informed consent or to comply with study requirements
  • Moderate to severe hepatic impairment, i.e., Child-Pugh Class B or C
  • AST and ∕or ALT > 3 times uln
  • Hemoglobin concentration > 25% below the lower limit of normal
  • Systolic blood pressure < 85 mm Hg
  • Pregnancy or breast-feeding
  • Treatment or planned treatment with another investigational drug
  • Treatment with an endothelin receptor antagonist, phosphodiesterase type 5 inhibitor, or with prostanoids (excluding acute administration during a catheterization procedure to test vascular reactivity) within 2 months of inclusion
  • Treatment with calcineurin-inhibitors (i.e., cyclosporine A and tacrolimus), fluconazole, glibenclamide (glyburide) within 1 week of study start;
  • Known hypersensitivity to bosentan or any of the excipients

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00864201


Contacts
Contact: Christine Bradley, MD 905-546-9993 mkenney@bellnet.ca

Locations
Canada, Ontario
Victoria Medical Center Not yet recruiting
Hamilton, Ontario, Canada, L8L 5G4
Principal Investigator: Christine Bradley, MD         
Sponsors and Collaborators
Hamilton Health Sciences Corporation
Actelion
Investigators
Principal Investigator: Christine Bradley Hamilton Health Sciences Corporation

Responsible Party: Dr. Christine Bradley, Victoria Medical Centre
ClinicalTrials.gov Identifier: NCT00864201     History of Changes
Other Study ID Numbers: PAH-CTD-2007
First Posted: March 18, 2009    Key Record Dates
Last Update Posted: March 18, 2009
Last Verified: March 2009

Additional relevant MeSH terms:
Hypertension
Familial Primary Pulmonary Hypertension
Connective Tissue Diseases
Hypertension, Pulmonary
Vascular Diseases
Cardiovascular Diseases
Lung Diseases
Respiratory Tract Diseases
Bosentan
Antihypertensive Agents
Endothelin Receptor Antagonists
Molecular Mechanisms of Pharmacological Action